Abstract
Metastatic upper tract urothelial carcinoma (mUTUC) often has poor prognosis. While systemic therapy is the standard care for mUTUC, lymph node dissection (LND) combined with radical nephroureterectomy (RNU) can be considered for patients with only clinical locoregional LN, resulting in a surgical cure. However, since pembrolizumab, an anti-PD-1 monoclonal antibody, was approved for mUTUC patients, prognosis of mUTUC has been improved and some patients with immune-related adverse events have experienced a clinical complete response and a long-lasting therapeutic response without surgery. Thus, clarifying the optimal patient selection and timing for RNU + LND is warranted to avoid unnecessary surgery. We herein report the first unique case with a clinical N + UTUC patient who underwent RNU plus LND and showed a pathological complete response after discontinuation of pembrolizumab due to adrenal insufficiency. We feel that our case may affect the treatment strategy for N + UTUC in the era of ICIs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets used during the current study are available from the corresponding author on reasonable request.
References
Rouprêt M, Seisen T, Birtle AJ et al (2023) European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2023 update. Eur Urol 84:49–64
Kolawa A, D’Souza A, Tulpule V (2023) Overview, diagnosis, and perioperative systemic therapy of upper tract urothelial carcinoma. Cancers. https://doi.org/10.3390/cancers15194813
Tufano A, Cordua N, Nardone V et al (2022) Prognostic significance of organ-specific metastases in patients with metastatic upper tract urothelial carcinoma. J Clin Med. https://doi.org/10.3390/jcm11185310
Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol Off J Eur Soc Med Oncol 30:970–976
Balar AV, Castellano DE, Grivas P et al (2023) Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Ann Oncol Off J Eur Soc Med Oncol 34:289–299
Goto Y, Tanaka S, Maruo M et al (2022) Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis. IJU case reports 5:304–307
Miyama Y, Kanao K, Uranishi K et al (2023) Complete response to pembrolizumab in a patient with recurrent and metastatic urothelial bladder carcinoma reflecting coexisting sarcomatoid subtype and glandular differentiation: a case report. Int Can Conf J 12:24–30
Lemke E, Sahasrabudhe D, Guancial E et al (2020) The role of metastasectomy in urothelial carcinoma: where are we in 2020? Clin Genitourin Can 18:e478–e483
Piontkowski AJ, Corsi N, Morisetty S et al (2022) Benefit of lymph node dissection in cN+ patients in the treatment of upper tract urothelial carcinoma: analysis of NCDB registry. Urol Oncol 40:409.e409-409.e417
Shigeta K, Matsumoto K, Ogihara K et al (2022) Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Urol Oncol 40:105.e119-105.e126
Ito K, Kita Y, Yokomizo A et al (2023) Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study. Cancer Med 12:2325–2332
Voskuilen CS, Schweitzer D, Jensen JB et al (2020) Diagnostic Value of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma. Eur Urol Oncol 3:73–79
Suzuki K, Terakawa T, Furukawa J et al (2020) Nivolumab-induced adrenal insufficiency in patients with renal cell carcinoma. J Immunother. https://doi.org/10.1097/CJI.0000000000000299
**ang J, Liu X, Hao Y et al (2023) Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced adrenal insufficiency. Transl Oncol 38:101787
Bhatlapenumarthi V, Patwari A, Harb AJ (2021) Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. J Cancer Res Clin Oncol 147:2789–2800
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have stated that they have no conflicts of interest.
Informed consent
Informed consent was obtained from the patient.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Suzuki, K., Murata, K., Wakita, N. et al. A pathological complete response and adrenal insufficiency in a patient with advanced renal pelvic cancer treated with pembrolizumab. Int Canc Conf J (2024). https://doi.org/10.1007/s13691-024-00695-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13691-024-00695-1